Physician profile
Jiyon Choi
NPI 1144437567
$19,954.06
in general payments reported to CMS, 2019-2025
73 companies · $3,508 in 2025
The $3,508 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $1,832 · 2021: $2,625 · 2022: $2,895 · 2023: $3,257 · 2024: $3,609 · 2025: $3,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,363.54 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,532.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,523.51 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $1,447.61 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $1,351.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,251.54 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Celgene Corporation | $1,224.84 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $920.50 | 2019-2025 | Xospata, Padcev, Vyloy |
| Glaxosmithkline, LLC. | $903.07 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $755.61 | 2019-2025 | Rybrevant, Akeega, Erleada |
| Eisai INC. | $707.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $632.97 | 2019-2025 | Alunbrig, Iclusig, Fruzaqla |
| Seagen INC. | $594.84 | 2019-2023 | Tukysa, Padcev |
| Genentech USA, INC. | $576.93 | 2019-2024 | Venclexta, Polivy, Tecentriq |
| Array Biopharma INC | $549.37 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $484.85 | 2019-2023 | Blincyto, Kyprolis |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiyon Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.